U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H27N5O2.ClH
Molecular Weight 477.986
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VILAZODONE HYDROCHLORIDE

SMILES

Cl.NC(=O)C1=CC2=C(O1)C=CC(=C2)N3CCN(CCCCC4=CNC5=C4C=C(C=C5)C#N)CC3

InChI

InChIKey=RPZBRGFNBNQSOP-UHFFFAOYSA-N
InChI=1S/C26H27N5O2.ClH/c27-16-18-4-6-23-22(13-18)19(17-29-23)3-1-2-8-30-9-11-31(12-10-30)21-5-7-24-20(14-21)15-25(33-24)26(28)32;/h4-7,13-15,17,29H,1-3,8-12H2,(H2,28,32);1H

HIDE SMILES / InChI

Description

Vilazodone is a serotonergic antidepressant. The mechanism of the antidepressant effect of vilazodone is not fully understood but is thought to be related to its inhancement of serotonergic activity in the CNS through selective inhibition of serotonin reuptake. Vilazodone is also a partial agonist at serotonergic 5-HT1A receptors; however, the net result of this action on serotonergic transmission and its role in vilazodone’s antidepressant effect are unknown. The side effects include activation of mania/hypomania in patients with bipolar disorder, seizures can occur with treatment in patients with a seizure disorder.

CNS Activity

Originator

Approval Year

PubMed

PubMed

TitleDatePubMed
Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies.
2014 Dec
A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
2014 Dec
Bioavailability comparison of a new form of vilazodone XVII to IV in beagles using liquid chromatography/mass spectrometry.
2014 Dec
Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
2014 Nov
Efficacy of vilazodone on anxiety symptoms in patients with major depressive disorder.
2014 Nov
A validated LC-MS/MS method for the rapid quantification of vilazodone in rat plasma: application to a pharmacokinetic study.
2014 Sep
Identification of hydrolytic and isomeric N-oxide degradants of vilazodone by on line LC-ESI-MS/MS and APCI-MS.
2015 Jan
Psychotropic exposures in pediatric patients: Symptomatic iloperidone and vilazodone ingestions.
2015 Mar
Issues encountered in recent attempts to develop novel antidepressant agents.
2015 May
Patents

Sample Use Guides

In Vivo Use Guide
Recommended target dosage: 20 mg to 40 mg once daily with food. To titrate: start with initial dosage of 10 mg once daily for 7 days, followed by 20 mg once daily. The dose may be increased up to 40 mg once daily after a minimum of 7 days between dosage increases. Prior to initiating VIIBRYD, screen for bipolar disorder.
Route of Administration: Oral
Name Type Language
VILAZODONE HYDROCHLORIDE
MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN  
Official Name English
VILAZODONE HYDROCHLORIDE [MART.]
Common Name English
5-(4-(4-(5-CYANO-1H-INDOL-3-YL)BUTYL)PIPERAZIN-1-YL)BENZOFURAN-2-CARBOXAMIDE MONOHYDROCHLORIDE
Systematic Name English
EMD 68 843
Code English
VILAZODONE HCL
Common Name English
SB-659746-A
Code English
VILAZODONE HYDROCHLORIDE [VANDF]
Common Name English
VILAZODONE HYDROCHLORIDE [WHO-DD]
Common Name English
VILAZODONE HYDROCHLORIDE [USAN]
Common Name English
2-BENZOFURANCARBOXAMIDE, 5-(4-(4-(5-CYANO-1H-INDOL-3-YL)BUTYL)-1-PIPERAZINYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
VILAZODONE HYDROCHLORIDE [MI]
Common Name English
EMD-68843
Code English
VIIBRYD
Common Name English
SB659746-A
Code English
VILAZODONE HYDROCHLORIDE [ORANGE BOOK]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C265
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
NCI_THESAURUS C47794
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
Code System Code Type Description
CAS
163521-08-2
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY
MERCK INDEX
M11446
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY Merck Index
ChEMBL
CHEMBL439849
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY
RXCUI
1086768
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY RxNorm
NCI_THESAURUS
C90717
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY
EVMPD
SUB32288
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY
PUBCHEM
6918313
Created by admin on Mon Oct 21 23:42:14 UTC 2019 , Edited by admin on Mon Oct 21 23:42:14 UTC 2019
PRIMARY